Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
FISH-X- PROVIDING A EUROPEAN FISHERIES DATASPACE THROUGH A CONSULTATIVE APPROACH (Fish-X)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Bio-Environment
Destination: Fair, healthy and environmentally-friendly food systems from primary production to consumption
Action type: Innovation actions
Countries involved: Germany,Portugal,Belgium,France,Italy,Croatia,Ireland
Call: Digital transition supporting inspection and control for sustainable fisheries (HORIZON-CL6-2021-FARM2FORK-01, 2021)
Start date: 2022-06-01
End date: 2025-05-31
Duration (months): 36.0
Total project cost (EUR): 6037180.68
EU funding (EUR): 4545488.63
Participants: 12
Project status: SIGNED

Developing a Fisheries DataSpace (Fish-X) and ‘Insight Platform – based on smart orchestrated architecture and open interoperable technology via Gaia-X - that will enable users to implement data to improve fishing methods, increase yields, protect endangered fisheries stocks and streamline MCS processes supporting the implemntation of the CFP. The project will also be developing a series of industry and Fisheries agency to consultatively participate in developing and refining new technologies in light of the changes and review of CFP.

Keywords: consultative approach,fisheries mcs implementation,just digital transition,
Hebrew Philosophical Manuscripts as Sites of Engagement (HEPMASITE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Texts and Concepts
Panel description: Literary studies , literature,  philosophy
Countries involved: Germany
Call: ERC STARTING GRANTS (ERC-2021-STG, 2021)
Start date: 2022-10-01
End date: 2027-09-30
Duration (months): 60.0
Total project cost (EUR): 1495013.0
EU funding (EUR): 1495013.0
Participants: 1
Project status: SIGNED

In the Middle Ages, philosophical activity undertaken in Hebrew was not conducted within an institutionalized environment. There were no universities, regulated curricula, or professors, but only small circles of scholars, most of whom we know nothing about. These scholars had to obtain their own copies of the works they wished to explore, sometimes even copying them themselves or with the help of others. Heavily involved in the production of the materials they were using, they often interfered with the texts they were studying, offering corrections, working notes, glosses, comparisons, and observations. As a result, the corpus of philosophical writings in Hebrew is incredibly diverse, and rarely is one copy similar to another. In this challenging landscape, the individual copy is our main entry point for understanding how Hebrew philosophy took place in the real world. The Hebrew philosophical manuscript is not a mere container of text; more than anything else, it is a site of engagement. Aside from a few notable exceptions, scholarship of philosophy in Hebrew is still focused on a relatively small number of major thinkers and works. Manuscripts are often stripped of their particularity and employed only for the sake of producing critical editions. The story of the silent, nameless majority - who enabled philosophical activity by tirelessly editing, studying, translating, revising, and producing the material Hebrew philosophical corpus we have today - has yet to be told. HEPMASITE is the first project to tackle the corpus of medieval Hebrew philosophical manuscripts in order to unravel the hidden history of Jewish philosophy enveloped within them. By employing narrative philology and a historiography of engagement - novel research methodologies that embrace textual particularity and fluidity - HEPMASITE will revolutionize the understanding of Jewish philosophy as it took place in the real world and as it was studied by actual people.

Keywords: jewish philosophy,hebrew manuscripts
Virtual Reality and AI for Real-Time Clinical Decision Support and Intracranial Aneurysm Risk Prediction (VRAI-CURE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: France
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2025-POC, 2025)
Start date: 2026-01-01
End date: 2027-06-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 2
Project status: SIGNED

Intracranial aneurysms (IAs) pose a severe neurovascular threat, with rupture leading toIntracranial aneurysms (IAs) pose a severe neurovascular threat, with rupture leading to life-threatening complications. Current treatment planning relies on static imaging and computational fluid dynamics, which are computationally expensive and lack real-time clinical integration. Clinicians face uncertainty in selecting optimal intervention strategies, increasing procedural risks and costs. VRAI-CURE proposes an AI-driven clinical decision support system that combines Physics-Constrained Graph Neural Networks for real-time hemodynamic simulation and immersive Virtual Reality (VR) visualization. This system enables instantaneous, patient-specific blood flow predictions, transforming clinical workflows by providing neurovascular specialists with actionable insights for treatment planning. Unlike conventional simulation or imaging methods, the proposed AI-based approach is computationally efficient, self-improving with each new patient case, and seamlessly integrates into standard imaging workflows (MRI, CT, angiography). By delivering an interactive VR-based visualization of blood flow dynamics, VRAI-CURE enhances clinical understanding of aneurysm behavior and treatment effects, facilitating personalized decision-making. Our preliminary validation demonstrates superior accuracy and efficiency compared to existing techniques, addressing a significant gap in neurovascular intervention. With the VR healthcare market projected to reach $40 billion by 2032, the transformative potential extends beyond neurovascular medicine, offering a cutting-edge solution in a rapidly expanding sector. This project aims to advance to TRL 6, developing a certified clinical prototype ready for industrial transfer. The project’s high-risk/high-gain potential positions it as a transformative innovation in precision neurovascular medicine, with broad implications for AI-driven clinical decision support.
Multi Material Additive Manufacturing with Electrostatic Cold Spray (MADECOLD)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Italy,Ireland,Germany,Lithuania
Call: EIC Pathfinder Open (HORIZON-EIC-2023-PATHFINDEROPEN-01, 2023)
Start date: 2024-06-01
End date: 2028-05-31
Duration (months): 48.0
Total project cost (EUR): 3463068.75
EU funding (EUR): 3463068.75
Participants: 5
Project status: SIGNED

While additive manufacturing (AM) is deemed the future of industrial production for its exceptional freedom in design, several technical limits hinder its full exploitation. Surprisingly, the most diffused AM techniques (e.g. LPBF) are associated with almost 4 times higher energy consumption compared to conventional manufacturing processes, while being also more limited in build rate, build size, material selection and surface quality. We need to re-invent AM to tackle these challenges and expand its market to uncharted areas. In MadeCold we will achieve a real breakthrough in this direction by merging solid state and electrostatic physics, control and monitoring, and mechanical design with material science to develop a disruptive solid state deposition process. The revolutionary principle of MadeCold is to charge and accelerate metal powders to supersonic velocities in a customized electric field and take benefit from the kinetic energy to induce bonding upon impact with a substrate; this has not been done before. Relying on our preliminary results, we will implement multiscale computational models and advanced experiments to develop a single launcher to prove bonding efficiency. Then via a new control system, we will pair multiple launchers to exhibit the capacity of MadeCold for covering simultaneously a theoretically unlimited surface, compared to the point-wise print of the current AM. We will demonstrate that it outperforms the existing technologies regarding the accuracy, deposition rate, flexibility and scalability and paves the way to depositing functional multi-material structures with unprecedented properties. We intend to prove this in 3 key sectors: aerospace, energy and hybrid manufacturing with specific proofs of concept. We are confident to achieve the overall objectives via a sophisticated multi-disciplinary approach based on scientific investigations, and the exploitation of discoveries to establish Europe as a leader in advanced manufacturing.

Keywords: metal additive manufacturing,solid state powder deposition,powder acceleration
Laser digital transfer of 2D materials enabled photonics: from the lab 2 the fab (L2D2)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Transition
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Greece,Spain,Israel
Call: EIC Transition Open 2021 (HORIZON-EIC-2021-TRANSITIONOPEN-01, 2021)
Start date: 2022-10-01
End date: 2025-12-31
Duration (months): 39.0
Total project cost (EUR): 2499975.0
EU funding (EUR): 2499975.0
Participants: 5
Project status: SIGNED

To unveil the true potential of graphene and 2D materials and address the increasing demand for industrial applications, it is essential to develop upscaling growth technologies which preserve the pristine quality at large wafer size and enable the wafer-scale integration of the material with a standardized process. Therefore, a green and solvent-free technology offering the solution to transfer single layer graphene and 2D materials in a single step, preserving the same quality in wafer scale processing constitutes a major breakthrough, with the potential to disrupt all the market segments associated with the emerging applications. This project, L2D2, builds upon the IP generated within the H2020-FET-open project LEAF-2D, to deliver the first scalable digital process for growing and integrating graphene (Gr) and the most prominent 2D materials (including MoTe2 and WS2) in terms of optoelectronic properties, quality and uniformity, onto Si photonics and CMOS compatible substrates on-demand. In particular, L2D2 will deliver a two-fold technological breakthrough: 1. The technology to upscale Gr and other 2D materials on the 8-inch scale at industrial grade quality 2. A laser-based, single-step and green printing solution for wafer-scale integration of 2D materials. The exploitable outcomes of L2D2 will lay the foundation for a deep-tech business model which will secure the foreground of the project and transform it to innovations with high exploitation potential. The business model will be realized through the creation of a spin out with a team of co-founders encompassing highly skilled entrepreneurs with equal expertise in technology, innovation and business. The spin-out will follow a viable and fast commercialization pathway, relying on strategic corporate agreements with the world leading companies in Graphene and Si photonics, as well as on IP exploitation.

Keywords: graphene,2d materials,laser induced forward transfer,si photonics,si emitters,business model innovation
Enhancing Climate-Resilient Crops by Innovative Priming Strategies (PRIMER)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Doctoral Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Czechia,Italy,United Kingdom,Spain,France,Cyprus,Belgium,Portugal,Israel,Switzerland,Ireland,United States
Call: MSCA Doctoral Networks 2024 (HORIZON-MSCA-2024-DN-01, 2024)
Start date: 2025-10-01
End date: 2029-09-30
Duration (months): 48.0
Total project cost (EUR): 3599188.92
EU funding (EUR): 3599188.92
Participants: 25
Project status: SIGNED

PRIMER addresses the escalating threat of climate change on agriculture, specifically the increasing frequency of heatwaves on food security. PRIMER is a network of 10 beneficiaries and 10 associated partners which aims to enhance the resilience of tomato using innovative priming approaches, including genetic, chemical and physiological interventions. PRIMER will train 12 doctoral candidates through projects that utilize multidisciplinary approaches and cutting-edge technologies to generate improved tomato yields and mitigate losses due to heat. In addition to the scientific training, PRIMER aims to (1) generate a single-cell gene expression atlas to decipher intricate cell- and tissue-specific priming mechanisms; (2) explore the genetic basis of priming by leveraging diverse tomato varieties, offering valuable germplasm for breeding; (3) develop computational models to predict plant responses under diverse heat stress scenarios, optimizing novel priming strategies; (4) pioneer interventions (physiological, chemical, and genetic) to bolster plant thermotolerance and enhance crop resilience. Each objective is addressed through dedicated WPs. PRIMER's approach spans from fundamental research elucidating cellular mechanisms to practical interventions aimed at mitigating the detrimental impacts of heat stress on crop productivity. By integrating state-of-the-art technologies like single-cell analysis, advanced genomics, computational biology, novel chemical priming stimulants and modern genetic approaches, the network bridges the gap between fundamental and applied research. PRIMER training on these techniques will empower the doctoral candidates with hands-on experience, fostering expertise at the forefront of plant stress biology. Moreover, the program emphasizes transferable skills such as interdisciplinary collaboration, communication, and leadership, ensuring researchers will address multifaceted challenges in sustainable agriculture.

Keywords: priming,yield,crop resilience,computational biology,genetics,single cell,thermotolerance
Instrumented human stem cells to see more during high throughput screening in drugInstrumented human stem cells to see more during high throughput screening in drug discovery and regenerative medicine (hiPSCmore)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Italy
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2023-POC, 2023)
Start date: 2024-05-01
End date: 2025-10-31
Duration (months): 18.0
Total project cost (EUR): 171428.57
EU funding (EUR): 150000.0
Participants: 2
Project status: SIGNED

In hiPSCmore (read hiP-See-More), my team and I will engineer fluorescent sensors in the DNA of human induced pluripotent stem cells (hiPSC) so we can “See More” during high-throughput imaging screenings (imHTS) for drug discovery and regenerative medicine. Since hiPSCs can differentiate in most cell types in the human body, they are the ideal cell source for more predictively screening therapies. Yet, hiPSCs are expensive to maintain and require external reagents to visualize pathophysiological changes, which adds to the screening cost and complexity. In fact, the major hurdle in adopting hiPSCs for imHTS has been the price increase from <0.10 $/data point to 2+ $/data point. In the context of our ERC Stg, we genetically encoded fluorescent sensors for cell structure, function, and cell cycle progression directly into hiPSCs for in-vitro modeling of heart development. With those sensors, we can visualize pathophysiological changes through reagents provided by the cells themselves. Thus, the more experiments we conduct, the cheaper they become. We believe this is the strategy to bring hiPSCs into imHTS, where testing millions of compounds vanishes an experiment's marginal cost. Like software. To explore this opportunity, we envision three main objectives. 1. Technology feasibility. We will scale up the production of our SeeMore hiPSCs and validate their cost-effectiveness in drug screening and regenerative medicine applications. 2. Business feasibility. We will analyze market dynamics and customer preferences in the drug screening and regenerative markets to define the most efficient go-to-market strategy. 3. Executive management. We will work with stakeholders in our advisory board to delineate IPR, business strategy, and future fundraising opportunities for a SeeMore spin-off company. Through these activities, the SeeMore spin-off will incorporate the right mix of tech development and business savvy in its own DNA, so it can "seize more" of the HTS market.
Clonal hematopoesis of indeterminate potential and degenerative aortic valve stenosis (CHIP-AVS)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Prevention,  Diagnosis and T reatment of Human Diseases
Panel description: Medical technologies  and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions , pharmacology, preventative  medicine, epidemiology and public health , digital medicine
Countries involved: Germany
Call: ERC ADVANCED GRANTS (ERC-2021-ADG, 2021)
Start date: 2022-11-01
End date: 2027-10-31
Duration (months): 60.0
Total project cost (EUR): 2225906.0
EU funding (EUR): 2225906.0
Participants: 1
Project status: SIGNED

Degenerative aortic valve stenosis is the most common acquire heart valve disease and will continue to increase as a result of an aging population. There is currently no medical therapy established to halt progression of aortic stenosis and the only definitive treatment is aortic valve replacement either by surgery or transcatheter aortic valve replacement (TAVR). Without valve replacement, the 2 year mortality rate approximates 50 % once patients are symptomatic. Although a number of general risk factors have been described for developing calcified aortic valve disease, risk prediction for progression of CAVD to severe stenosis is still poor. We demonstrated that somatic mutations associated with expansion of hematopoietic cells (“clonal haematopoiesis“ (CH)) are associated with a poor prognosis of patients with aortic valve stenosis undergoing TAVR. This application aims to address the following major points. We will determine 1) how mutations in the most prevalent CH-driver gene DNMT3A may directly or indirectly affect the pathophysiological processes leading to aortic valve stenosis, and 2) which type of mutation is particularly involved in mediating the poor prognosis. 3) We will determine the impact of CH on the reversibility of cardiac fibrosis after successful replacement of the aortic valve, and 4) determine the relation of CH with senescence and inflammaging. We will use cutting edge single cell and omics technologies to decipher the pathophysiological effects in patient tissues and circulating blood samples and will explore the pathomechanisms induced by DNMT3A CH-driver mutation by assessing cellular communication processes in vitro. The discovery of relevant of immune system mediated complexities in the progression of aortic valve stenosis and consequent cardiac fibrosis is expected to identify biomarkers and possible novel therapeutic targets to specifically intervene in patients with a high risk for worse outcome.
RESILIENCE Preparatory Phase Project (RESILIENCE PPP)

Framework: Horizon Europe — Excellent Science
Programme: Research infrastructures
Theme: Research infrastructures
Destination: Development and infrastructures
Action type: Coordination and support actions
Countries involved: Italy,Israel,France,Germany,Belgium,Bulgaria,Netherlands,Albania,Bosnia and Herzegovina,Poland,Greece
Call: Preparatory phase of new ESFRI research infrastructure projects (HORIZON-INFRA-2021-DEV-02, 2021)
Start date: 2022-06-01
End date: 2026-05-31
Duration (months): 48.0
Total project cost (EUR): 4313005.0
EU funding (EUR): 3981620.75
Participants: 13
Project status: SIGNED

RESILIENCE (Religious Studies Infrastructure: tooLs, Innovation, Experts, conNections and Centres in Europe) is a distributed Research Infrastructure that entered the ESFRI Roadmap in 2021. Its mission is to address the challenge of creating a larger, structured involvement of excellent scholars who innovatively produce competencies, knowledge, approaches, and impact within the scientific domain of Religious Studies. The main objective of the RESILIENCE Preparatory Phase Project (PPP) proposal is to bring the RI to the completion of its Preparatory Phase, which started in 2021 and will end in 2025. The work includes legal, governance, financial, technical, strategic, and administrative aspects carried out in 6 work packages. The primary outcomes of the PPP are the setting-up of the legal and financial frameworks of the functioning of the RI; the preparation of signature-ready documents towards the implementation phase; the completion of the RESILIENCE service catalogue, and the establishment of legal agreements and technical frameworks for their operation.